30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

AtaiBeckley Inc (ATAI)

Track

Over the last 90 days, AtaiBeckley Inc. has seen 5 insider transactions totaling $4.09 million in sales, with no reported buys. Notably, Director Cosmo Feilding-Mellen and Officer Kevin James Craig have made significant proposed sales. The company's stock has seen a 15.7% increase in the past 90 days.
Stock chart
Ticker: ATAI Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Craig Kevin James
Chief Medical Officer
1 sale — total 212,895 USD
Planned sale 20 Apr 2026
Value US$1,632,993.88 | Price 336.19 | Shares 30,813
Proposed sale 20 Apr 2026
Value US$695,135.38 | Price 319.16 | Shares 90,926
Planned sale 20 Mar 2026
Value US$355,000.00 | Price 3.55 | Shares 100,000
Proposed sale 20 Mar 2026
Value US$357,000.00 | Price 3.57 | Shares 100,000
Proposed sale 11 Mar 2026
Value US$2,991,525.00 | Price 3.99 | Shares 750,000
Proposed sale 26 Feb 2026
Value US$3,000,000.00 | Price 4.00 | Shares 750,000
Sale 2 Jan 2026
Value US$154,377.01 | Price 3.90 | Shares 39,594
Buy 14 Aug 2025
Value US$18,999,999.81 | Price 2.19 | Shares 8,675,799
Proposed sale 2 Jul 2025
Value US$233,829.59 | Price 2.81 | Shares 83,332
Proposed sale 1 Jul 2025
Value US$294,380.54 | Price 2.77 | Shares 106,093
Proposed sale 4 Jun 2025
Value US$198,408.00 | Price 2.48 | Shares 80,000
Proposed sale 24 Mar 2025
Value US$154,090.00 | Price 1.54 | Shares 100,000
Buy 24 Mar 2025
Value US$2,520,000.00 | Price 1.40 | Shares 1,800,000
Sale 21 Mar 2025
Value US$45,285.75 | Price 1.35 | Shares 33,545
Proposed sale 21 Mar 2025
Value US$46,627.55 | Price 1.39 | Shares 33,545
Sale 21 Mar 2025
Value US$65,560.05 | Price 1.35 | Shares 48,563
Proposed sale 21 Mar 2025
Value US$67,502.57 | Price 1.39 | Shares 48,563
Sale 21 Mar 2025
Value US$17,767.35 | Price 1.35 | Shares 13,161
Proposed sale 21 Mar 2025
Value US$18,293.79 | Price 1.39 | Shares 13,161
Sale 21 Mar 2025
Value US$101,814.30 | Price 1.35 | Shares 75,418
Proposed sale 21 Mar 2025
Value US$104,831.02 | Price 1.39 | Shares 75,418
Sale 21 Mar 2025
Value US$15,610.05 | Price 1.35 | Shares 11,563
Proposed sale 21 Mar 2025
Value US$16,072.57 | Price 1.39 | Shares 11,563
Proposed sale 20 Mar 2025
Value US$412,560.00 | Price 1.38 | Shares 300,000
Proposed sale 19 Mar 2025
Value US$256,386.89 | Price 1.39 | Shares 184,451
Buy 14 Feb 2025
Value US$22,755,007.80 | Price 2.10 | Shares 10,835,718
Sale 16 May 2024
Value US$290,501.76 | Price 1.92 | Shares 151,303
Proposed sale 3 May 2024
Value US$20,952.59 | Price 2.25 | Shares 9,333
Proposed sale 8 Apr 2024
Value US$42,253.96 | Price 2.52 | Shares 16,777
Proposed sale 5 Apr 2024
Value US$15,997.12 | Price 2.49 | Shares 6,423
Proposed sale 4 Apr 2024
Value US$19,738.00 | Price 2.78 | Shares 7,100
Proposed sale 4 Apr 2024
Value US$1,577.44 | Price 2.47 | Shares 639
Proposed sale 3 Apr 2024
Value US$228,031.12 | Price 2.13 | Shares 107,046
Sale 2 Apr 2024
Value US$66,231.85 | Price 1.85 | Shares 35,801
Sale 2 Apr 2024
Value US$50,708.50 | Price 1.85 | Shares 27,410
Sale 2 Apr 2024
Value US$114,034.00 | Price 1.85 | Shares 61,640
Buy 16 Nov 2023
Value US$23,120.00 | Price 1.16 | Shares 20,000
Buy 13 Sep 2023
Value US$57,968.00 | Price 1.45 | Shares 40,000
Buy 29 Mar 2023
Value US$103,558.00 | Price 1.48 | Shares 70,000
Buy 29 Mar 2023
Value US$1,600,443.45 | Price 1.32 | Shares 1,214,297
Buy 29 Apr 2022
Value US$97,801.02 | Price 4.47 | Shares 21,900
Buy 28 Apr 2022
Value US$154,689.13 | Price 4.46 | Shares 34,700
Buy 27 Apr 2022
Value US$91,939.39 | Price 4.64 | Shares 19,803
Buy 26 Apr 2022
Value US$216,627.66 | Price 4.69 | Shares 46,207
Buy 25 Apr 2022
Value US$42,842.54 | Price 4.78 | Shares 8,961
Buy 22 Apr 2022
Value US$254,962.14 | Price 4.83 | Shares 52,820
Buy 21 Apr 2022
Value US$340,039.94 | Price 4.95 | Shares 68,688
Buy 20 Apr 2022
Value US$344,513.49 | Price 5.09 | Shares 67,703
Buy 19 Apr 2022
Value US$334,739.38 | Price 5.13 | Shares 65,315
Buy 18 Apr 2022
Value US$277,656.04 | Price 5.11 | Shares 54,322
Buy 14 Apr 2022
Value US$25,778.73 | Price 5.19 | Shares 4,967
Buy 12 Apr 2022
Value US$269,560.07 | Price 4.88 | Shares 55,197
Buy 11 Apr 2022
Value US$260,554.25 | Price 4.83 | Shares 53,926
Buy 8 Apr 2022
Value US$277,639.85 | Price 4.81 | Shares 57,689
Buy 22 Jun 2021
Value US$10,500,000.00 | Price 15.00 | Shares 700,000
Buy 22 Jun 2021
Value US$69,990.00 | Price 15.00 | Shares 4,666
Buy 22 Jun 2021
Value US$69,990.00 | Price 15.00 | Shares 4,666
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-04-22 2026-04-20 PlS Planned sale
0.6
Craig Kevin James

Chief Medical Officer

Officer
30,813 +30.9%
336.19
US$1,632,994 		30,813 +30.9% 336.19 US$1,632,994
2026-04-20 2026-04-20 PrS Proposed sale
0.6
KEVIN JAMES CRAIG

Officer

Officer
90,926
319.16
US$695,135 		90,926 319.16 US$695,135
2026-03-24 2026-03-20 PlS Planned sale
0.6
Craig Kevin James

Chief Medical Officer

Officer
21,170 -24.0%
447.11
US$3,431,589 		21,170 -24.0% 447.11 US$3,431,589
2026-03-20 2026-03-20 PrS Proposed sale
0.6
KEVIN JAMES CRAIG

Officer

Officer
100,000
3.57
US$357,000 		100,000 3.57 US$357,000
2026-03-11 2026-03-11 PrS Proposed sale
2.1
Feilding-Mellen Cosmo

Director

Non-Executive Director
750,000
3.99
US$2,991,525 		750,000 3.99 US$2,991,525
2026-02-26 2026-02-26 PrS Proposed sale
2.1
Feilding-Mellen Cosmo

Director

Non-Executive Director
750,000
4.00
US$3,000,000 		750,000 4.00 US$3,000,000
2026-01-06 2026-01-02 S Sale
2.1
Feilding-Mellen Cosmo
Non-Executive Director
39,594 -0.5%
3.90
US$154,377 		39,594 -0.5% 3.90 US$154,377
2025-08-18 2025-08-14 B Purchase
2.5
Apeiron Investment Group Ltd.
Large shareholder
8,675,799 +20.5%
2.19
US$19,000,000 		8,675,799 +20.5% 2.19 US$19,000,000
2025-07-02 2025-07-02 PrS Proposed sale
1.5
SAHIL KIRPEKAR

Officer

Officer
83,332
2.81
US$233,830 		83,332 2.81 US$233,830
2025-07-01 2025-07-01 PrS Proposed sale
1.5
SAHIL KIRPEKAR

Officer

Officer
106,093
2.77
US$294,381 		106,093 2.77 US$294,381
2025-06-04 2025-06-04 PrS Proposed sale
1.5
SAHIL KIRPEKAR

Officer

Officer
80,000
2.48
US$198,408 		80,000 2.48 US$198,408
2025-03-24 2025-03-24 PrS Proposed sale
3.2
FLORIAN BRAND

Officer

Officer
100,000
1.54
US$154,090 		100,000 1.54 US$154,090
2025-03-24 2025-03-24 B Purchase
2.5
Apeiron Investment Group Ltd.
Large shareholder
1,800,000 +4.4%
1.40
US$2,520,000 		1,800,000 +4.4% 1.40 US$2,520,000
2025-03-24 2025-03-21 S Sale
1.5
Johnson Anne Nagengast

Chief Financial Officer

Officer
33,545 -19.3%
1.35
US$45,286 		33,545 -19.3% 1.35 US$45,286
2025-03-24 2025-03-21 S Sale
1.5
Kirpekar Sahil

Chief Business Officer

Officer
48,563 -29.6%
1.35
US$65,560 		48,563 -29.6% 1.35 US$65,560
2025-03-24 2025-03-21 S Sale
0.6
Short Glenn Frank

Chief Scientific Officer

Officer
13,161 -23.7%
1.35
US$17,767 		13,161 -23.7% 1.35 US$17,767
2025-03-24 2025-03-21 S Sale
1.8
Rao Srinivas

See Remarks

Officer
75,418 -26.2%
1.35
US$101,814 		75,418 -26.2% 1.35 US$101,814
2025-03-24 2025-03-21 S Sale
0.6
Craig Kevin James

Chief Medical Officer

Officer
11,563 -57.8%
1.35
US$15,610 		11,563 -57.8% 1.35 US$15,610
2025-03-21 2025-03-21 PrS Proposed sale
0.6
Craig Kevin James

Officer

Officer
11,563
1.39
US$16,073 		11,563 1.39 US$16,073
2025-03-21 2025-03-21 PrS Proposed sale
0.6
Short Glenn Frank

Officer

Officer
13,161
1.39
US$18,294 		13,161 1.39 US$18,294
2025-03-21 2025-03-21 PrS Proposed sale
1.5
Johnson Anne Nagengast

Officer

Officer
33,545
1.39
US$46,628 		33,545 1.39 US$46,628
2025-03-21 2025-03-21 PrS Proposed sale
1.8
Rao Srinivas

Officer

Officer
75,418
1.39
US$104,831 		75,418 1.39 US$104,831
2025-03-21 2025-03-21 PrS Proposed sale
1.5
Kirpekar Sahil

Officer

Officer
48,563
1.39
US$67,503 		48,563 1.39 US$67,503
2025-03-20 2025-03-20 PrS Proposed sale
3.2
FLORIAN OLAF BRAND

Officer

Officer
300,000
1.38
US$412,560 		300,000 1.38 US$412,560
2025-03-21 2025-03-19 PrS Proposed sale
3.2
Brand Florian

Former Officer

Officer
184,451
1.39
US$256,387 		184,451 1.39 US$256,387
2025-02-19 2025-02-14 B Purchase
2.5
Apeiron Investment Group Ltd.
Large shareholder
10,835,718 +36.5%
2.10
US$22,755,008 		10,835,718 +36.5% 2.10 US$22,755,008
2024-05-20 2024-05-16 S Sale
3.2
Brand Florian

See Remarks

Officer
151,303 -31.5%
1.92
US$290,502 		151,303 -31.5% 1.92 US$290,502
2024-05-03 2024-05-03 PrS Proposed sale
3.6
STEPHEN BARDIN

Officer

Officer
9,333
2.25
US$20,953 		9,333 2.25 US$20,953
2024-04-08 2024-04-08 PrS Proposed sale
3.6
STEPHEN BARDIN

Officer

Officer
16,777
2.52
US$42,254 		16,777 2.52 US$42,254
2024-04-05 2024-04-05 PrS Proposed sale
3.6
STEPHEN BARDIN

Officer

Officer
6,423
2.49
US$15,997 		6,423 2.49 US$15,997
2024-04-04 2024-04-04 PrS Proposed sale
3.6
STEPHEN BARDIN

Officer

Officer
7,100
2.78
US$19,738 		7,100 2.78 US$19,738
2024-04-04 2024-04-04 PrS Proposed sale
3.6
STEPHEN BARDIN

Officer

Officer
639
2.47
US$1,577 		639 2.47 US$1,577
2024-04-03 2024-04-03 PrS Proposed sale
3.6
STEPHEN BARDIN

Officer

Officer
107,046
2.13
US$228,031 		107,046 2.13 US$228,031
2024-04-04 2024-04-02 S Sale
1.5
Kirpekar Sahil

Chief Business Officer

Officer
35,801 -35.8%
1.85
US$66,232 		35,801 -35.8% 1.85 US$66,232
2024-04-04 2024-04-02 S Sale
1.5
Johnson Anne Nagengast

Chief Financial Officer

Officer
27,410 -27.1%
1.85
US$50,708 		27,410 -27.1% 1.85 US$50,708
2024-04-04 2024-04-02 S Sale
1.8
Rao Srinivas

See Remarks

Officer
61,640 -35.2%
1.85
US$114,034 		61,640 -35.2% 1.85 US$114,034
2023-11-20 2023-11-16 B Purchase
3.2
Brand Florian

See Remarks

Officer
20,000 +18.2%
1.16
US$23,120 		20,000 +18.2% 1.16 US$23,120
2023-09-14 2023-09-13 B Purchase
3.2
Brand Florian

See Remarks

Officer
40,000 +57.1%
1.45
US$57,968 		40,000 +57.1% 1.45 US$57,968
2023-03-30 2023-03-29 B Purchase
3.2
Brand Florian

See Remarks

Officer
70,000 +inf%
1.48
US$103,558 		70,000 +inf% 1.48 US$103,558
2023-03-29 2023-03-29 B Purchase
2.5
Apeiron Investment Group Ltd.
Large shareholder
1,214,297 +3.9%
1.32
US$1,600,443 		1,214,297 +3.9% 1.32 US$1,600,443
2022-05-02 2022-04-29 B Purchase
2.5
Apeiron Investment Group Ltd.
Large shareholder
21,900 +1.2%
4.47
US$97,801 		21,900 +1.2% 4.47 US$97,801
2022-05-02 2022-04-28 B Purchase
2.5
Apeiron Investment Group Ltd.
Large shareholder
34,700 +2.0%
4.46
US$154,689 		34,700 +2.0% 4.46 US$154,689
2022-04-28 2022-04-27 B Purchase
2.5
Apeiron Investment Group Ltd.
Large shareholder
19,803 +1.1%
4.64
US$91,939 		19,803 +1.1% 4.64 US$91,939
2022-04-28 2022-04-26 B Purchase
2.5
Apeiron Investment Group Ltd.
Large shareholder
46,207 +2.8%
4.69
US$216,628 		46,207 +2.8% 4.69 US$216,628
2022-04-26 2022-04-25 B Purchase
2.5
Apeiron Investment Group Ltd.
Large shareholder
8,961 +0.5%
4.78
US$42,843 		8,961 +0.5% 4.78 US$42,843
2022-04-26 2022-04-22 B Purchase
2.5
Apeiron Investment Group Ltd.
Large shareholder
52,820 +3.3%
4.83
US$254,962 		52,820 +3.3% 4.83 US$254,962
2022-05-03 2022-04-21 B Purchase
2.5
Apeiron Investment Group Ltd.
Large shareholder
68,688 +4.4%
4.95
US$340,040 		68,688 +4.4% 4.95 US$340,040
2022-05-03 2022-04-20 B Purchase
2.5
Apeiron Investment Group Ltd.
Large shareholder
67,703 +4.6%
5.09
US$344,513 		67,703 +4.6% 5.09 US$344,513
2022-04-20 2022-04-19 B Purchase
2.5
Apeiron Investment Group Ltd.
Large shareholder
65,315 +4.6%
5.13
US$334,739 		65,315 +4.6% 5.13 US$334,739
2022-04-20 2022-04-18 B Purchase
2.5
Apeiron Investment Group Ltd.
Large shareholder
54,322 +4.0%
5.11
US$277,656 		54,322 +4.0% 5.11 US$277,656
2022-04-18 2022-04-14 B Purchase
2.5
Apeiron Investment Group Ltd.
Large shareholder
4,967 +0.4%
5.19
US$25,779 		4,967 +0.4% 5.19 US$25,779
2022-04-14 2022-04-12 B Purchase
2.5
Apeiron Investment Group Ltd.
Large shareholder
55,197 +4.3%
4.88
US$269,560 		55,197 +4.3% 4.88 US$269,560
2022-04-12 2022-04-11 B Purchase
2.5
Apeiron Investment Group Ltd.
Large shareholder
53,926 +4.3%
4.83
US$260,554 		53,926 +4.3% 4.83 US$260,554
2022-04-12 2022-04-08 B Purchase
2.5
Apeiron Investment Group Ltd.
Large shareholder
57,689 +4.9%
4.81
US$277,640 		57,689 +4.9% 4.81 US$277,640
2021-06-24 2021-06-22 B Purchase
Angermayer Christian
Non-Executive Director Large shareholder
700,000 +3.6%
15.00
US$10,500,000 		700,000 +3.6% 15.00 US$10,500,000
2021-06-24 2021-06-22 B Purchase
1.4
WEAVER GREGORY L

Chief Financial Officer

Officer
4,666 +inf%
15.00
US$69,990 		4,666 +inf% 15.00 US$69,990
2021-06-24 2021-06-22 B Purchase
Auerbach Michael
Non-Executive Director
4,666 +0.1%
15.00
US$69,990 		4,666 +0.1% 15.00 US$69,990
Explore more

More insider trading research around AtaiBeckley Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America